Department of Family Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan-si, Republic of Korea.
Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea.
Thyroid. 2020 Oct;30(10):1496-1504. doi: 10.1089/thy.2019.0699. Epub 2020 Jul 15.
The association of metabolic syndrome and its components with the risk of thyroid cancer is unclear. Thus, we conducted a large-scale, nationwide, population-based, cohort study to investigate this relationship. We studied 9,890,917 adults without thyroid cancer from the Korean National Health Insurance health checkup database from January 1 to December 31, 2009. Individuals with at least three of the following five components were diagnosed with metabolic syndrome: abdominal obesity, hypertriglyceridemia, low high-density lipoprotein-cholesterol levels, elevated blood pressure, and hyperglycemia. Multivariate Cox proportional hazards models were used to estimate thyroid cancer risk. During the average 7.2 years of follow-up, 77,133 thyroid cancer cases were newly identified. The thyroid cancer risk was higher in the metabolic syndrome group than in the nonmetabolic syndrome group (hazard ratio [HR] 1.15 [95% confidence interval, CI 1.13-1.17]). The association between metabolic syndrome and thyroid cancer risk was significant in the obese group (HR 1.10 [CI 1.07-1.13]) and not in the nonobese group (HR 1.002 [CI 0.98-1.03]). The effect of metabolic syndrome on the risk of thyroid cancer differs according to obesity ( for interaction = 0.017). People with all five components of metabolic syndrome had a 39% higher risk than those without any components (HR 1.39 [CI 1.33-1.44]). The higher risk of thyroid cancer in people with all five components was significant in the obese group (HR 1.29 [CI 1.21-1.38]), but not in the nonobese group (HR 1.06 [CI 0.98-1.14]). There was a significant interaction between the number of metabolic syndrome components and obesity ( for interaction <0.0001). For the combined effect of obesity and metabolic syndrome on the risk of thyroid cancer, obese men with metabolic syndrome had the highest risk of thyroid cancer compared with those without (HR 1.58 [CI 1.52-1.64]), but obese women with metabolic syndrome did not. Metabolic syndrome was associated with an increased risk of thyroid cancer in the Korean general population. Metabolic syndrome had a more significant risk of thyroid cancer in the obese group. Metabolic syndrome and obesity were associated with a higher risk of thyroid cancer in men but not in women.
代谢综合征及其组分与甲状腺癌风险的关联尚不清楚。因此,我们开展了一项大规模的、全国性的、基于人群的队列研究,以调查这种关系。我们研究了 2009 年 1 月 1 日至 12 月 31 日期间来自韩国国民健康保险健康检查数据库的 9890917 名没有甲状腺癌的成年人。至少有以下五个成分中的三个被诊断为代谢综合征:腹部肥胖、高甘油三酯血症、低高密度脂蛋白胆固醇水平、血压升高和高血糖。多变量 Cox 比例风险模型用于估计甲状腺癌风险。在平均 7.2 年的随访期间,新确诊了 77133 例甲状腺癌病例。代谢综合征组的甲状腺癌风险高于非代谢综合征组(风险比 [HR] 1.15 [95%置信区间,CI 1.13-1.17])。在肥胖组(HR 1.10 [CI 1.07-1.13])而非非肥胖组(HR 1.002 [CI 0.98-1.03])中,代谢综合征与甲状腺癌风险之间存在显著关联。代谢综合征对甲状腺癌风险的影响因肥胖程度而异(交互作用 = 0.017)。患有代谢综合征的全部五个成分的人比没有任何成分的人患甲状腺癌的风险高 39%(HR 1.39 [CI 1.33-1.44])。肥胖组中患有全部五个成分的代谢综合征的人患甲状腺癌的风险更高(HR 1.29 [CI 1.21-1.38]),而非肥胖组则没有(HR 1.06 [CI 0.98-1.14])。代谢综合征成分的数量与肥胖之间存在显著的交互作用(交互作用<0.0001)。对于肥胖和代谢综合征对甲状腺癌风险的综合影响,与没有代谢综合征的肥胖男性相比,患有代谢综合征的肥胖男性患甲状腺癌的风险最高(HR 1.58 [CI 1.52-1.64]),但患有代谢综合征的肥胖女性则没有。代谢综合征与韩国一般人群中甲状腺癌风险的增加有关。代谢综合征在肥胖组中对甲状腺癌的风险更大。代谢综合征和肥胖与男性甲状腺癌风险的增加相关,但与女性无关。